Loading...
Loading...
Foundation
Medicine today announced new data from a pilot study demonstrating
that its fully informative genomic profile for hematologic malignancies,
FoundationOne™ Heme, identified both novel and previously reported
clinically actionable1 genomic alterations in multiple
myeloma cases. These data were presented in an oral presentation titled Pilot
Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In
Patients With Relapsed Refractory Multiple Myeloma (abstract number
755) by Alexander Lesokhin, M.D., medical oncologist, Memorial
Sloan-Kettering Cancer Center, at the 55th American Society
of Hematology Annual Meeting in New Orleans.#ASH13
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in